Guildford, UK - Philips Healthcare’s new AlluraClarity family of next generation interventional X-ray systems comes with Philips’ unique ClarityIQ technology that dramatically reduces X-ray dose (typically by 73 percent in neuro, 50 percent in cardiac and 83 percent in vascular interventional procedures), while delivering equivalent or better image quality. ClarityIQ pushes the boundaries of the ALARA (As Low as Reasonably Achievable) principle, so that patient and staff risks from radiation exposure are radically reduced, and longer and more complex procedures can now be performed more safely.
Philips Healthcare in the UK has already secured a commitment for the new equipment, with The Royal Victoria Hospital, Belfast being the first institution in the UK to place an order for the AlluraClarity.
ClarityIQ technology incorporates powerful state-of-the-art image processing technology, developed by Philips Research, all working in real-time, enabled by the latest computing technology, to assure optimum image quality with noise and artefact reduction (also on moving structures and objects); image enhancement and edge sharpening, and automatic real-time patient and accidental table motion correction on live images. As a result, this comprehensive set of system-wide improvements virtually eliminates the trade-off between X-ray dose and image quality.
The new technology utilises a flexible digital imaging pipeline from tube to display that is tailored for each and every application area from cardiac to neuro studies. This gives the flexibility to select virtually unlimited application-specific configurations and obtain superb images at a fraction of the X-ray dose for every intervention. In addition, with ClarityIQ, over five hundred system parameters are fine-tuned for each application area, the result of years of Philips’ clinical leadership, so that it is now possible to filter out more X-ray radiation, use smaller focal spot sizes, shorter pulses, thereby fully utilising the unique capabilities of the Philips MRC X-ray tube and Philips’ exclusive 2K imaging.
Findings from a recently landmark clinical trial conducted at the Karolinska Hospital in Stockholm demonstrated that Philips’ AlluraClarity with ClarityIQ technology provided equivalent image quality at 73 percent less dose and helped to eliminate the interventional X-ray trade-off between image quality and radiation dose, underscoring Philips’ commitment to patient safety. In the trial, independent neuro-radiologists compared images from two neurological digital subtraction angiography runs on the same patient, the first using Philips’ current Allura Xper system and the second using the new Philips AlluraClarity with ClarityIQ. The results of the study showed that the AlluraClarity provides equivalent image quality at 73 percent less dose.
“We were willing to accept that the image quality would decrease because we thought 73 percent X-ray dose reduction is so significant, but in the end, image quality actually improved,” said Dr. Michael Söderman, Karolinska Hospital, Stockholm, Sweden.
A potential site has now been identified that will investigate the use of AlluraClarity in cardiac angiography. In this study, images from two cardiac angiographies conducted on the same patient will be compared, one using the current Philips’ interventional system and the other with AlluraClarity. Preliminary data from a field test indicated that fifty percent of the dose can provide equivalent image quality when compared to images from the current interventional system.
Mike Hayden, Sales Director Imaging Systems, Philips Healthcare says, “In the past, it was difficult to combine great image quality and low dose in interventional X-ray, and it often resulted in trade-offs. The Philips AlluraClarity incorporates powerful imaging technology to bring superb image quality at a fraction of the dose, further proving Philips’ commitment to reducing the need to make compromises in patient care.”